Cargando…

Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma

BACKGROUND: Osteosarcoma is one of the most common bone cancers in children. Most patients with metastatic osteosarcoma die of pulmonary disease and limited curative therapeutic options exist for such patients. We have previously shown that PD-1 limits the efficacy of CTL to mediate immune control o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lussier, Danielle M, Johnson, John L, Hingorani, Pooja, Blattman, Joseph N
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4437699/ https://www.ncbi.nlm.nih.gov/pubmed/25992292 http://dx.doi.org/10.1186/s40425-015-0067-z

Ejemplares similares

Enhancement of T cell immunity to osteosarcoma through modulation of PD-1/PD-L1 interactions
por: Lussier, Danielle M, et al.
Publicado: (2013)

Impact of prophylactic TNF blockade in the dual PD-1 and CTLA-4 immunotherapy efficacy and toxicity
por: Alvarez, Maite, et al.
Publicado: (2019)

Antimesothelioma Immunotherapy by CTLA-4 Blockade Depends on Active PD1-Based TWIST1 Vaccination
por: Tan, Zhiwu, et al.
Publicado: (2020)

Irradiation enhanced the effects of PD-1 blockade in brain metastatic osteosarcoma
por: Xia, Liming, et al.
Publicado: (2018)

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
por: Callahan, Margaret K., et al.
Publicado: (2015)

A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
por: Du, Xuexiang, et al.
Publicado: (2018)

The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition
por: Kreidieh, Firas Y., et al.
Publicado: (2023)

Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer
por: Wada, Satoshi, et al.
Publicado: (2013)

Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers
por: Nebot-Bral, Laetitia, et al.
Publicado: (2022)

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
por: Heinzerling, Lucie, et al.
Publicado: (2016)

Correction: Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers
Publicado: (2022)

PD-1/CTLA-4 Blockade Leads to Expansion of CD8(+)PD-1(int) TILs and Results in Tumor Remission in Experimental Liver Cancer
por: Bufe, Sandra, et al.
Publicado: (2022)

Successful Treatment of Myasthenia Gravis Following PD-1/CTLA-4 Combination Checkpoint Blockade in a Patient With Metastatic Melanoma
por: Werner, Jan-Michael, et al.
Publicado: (2019)

Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma
por: Lim, Darren Wan-Teck, et al.
Publicado: (2023)

Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-α
por: Tezera, Liku B, et al.
Publicado: (2020)

CTLA4 blockade increases Th17 cells in patients with metastatic melanoma
por: von Euw, Erika, et al.
Publicado: (2009)

Combination Immunotherapy with 4-1BBL and CTLA-4 Blockade for the Treatment of Prostate Cancer
por: Youlin, Kuang, et al.
Publicado: (2012)

Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
por: Fan, Xiaozhou, et al.
Publicado: (2014)

The research status of immune checkpoint blockade by anti-CTLA4 and anti-PD1/PD-l1 antibodies in tumor immunotherapy in China: A bibliometrics study
por: Zhao, Xiaoqin, et al.
Publicado: (2018)

Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer
por: Huang, Ruea-Yea, et al.
Publicado: (2016)

Using the Spleen as an In Vivo Systemic Immune Barometer Alongside Osteosarcoma Disease Progression and Immunotherapy with α-PD-L1
por: Markel, Justin E., et al.
Publicado: (2018)

CD47/SIRPα pathway mediates cancer immune escape and immunotherapy
por: Jia, Xiao, et al.
Publicado: (2021)

Modulation of Cell Signaling Networks after CTLA4 Blockade in Patients with Metastatic Melanoma
por: Comin-Anduix, Begoña, et al.
Publicado: (2010)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

ODP342 Panhypopituitarism Induced by CTLA-4 and PD-1/PD-L1 Inhibitor Immunotherapy
por: Hernandez-Cordero, Nicole, et al.
Publicado: (2022)

Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy
por: Shi, Lewis Zhichang, et al.
Publicado: (2016)

Application of PD-1 Blockade in Cancer Immunotherapy
por: Wu, Xiaomo, et al.
Publicado: (2019)

Exceptional response to PD-1 inhibition immunotherapy in advanced metastatic osteosarcoma with tumor site infection
por: Li, Meng, et al.
Publicado: (2022)

CTLA-4 blockade and interferon-α induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma
por: Khunger, Arjun, et al.
Publicado: (2021)

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015)

CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy
por: Brunner-Weinzierl, Monika C., et al.
Publicado: (2018)

TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
por: Bertrand, Florie, et al.
Publicado: (2017)

Combination immunotherapy with Interleukin-2 and CTLA-4 blockade decreases tumor growth and improves overall survival
por: Broucek, Joseph R, et al.
Publicado: (2013)

Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma
por: Retseck, Janet, et al.
Publicado: (2018)

Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?
por: Tang, Fei, et al.
Publicado: (2018)

PD-1 Blockade on Tumor Microenvironment-Resident ILC2s Promotes TNF-α Production and Restricts Progression of Metastatic Melanoma
por: Howard, Emily, et al.
Publicado: (2021)

TGF-β1 Induces Immune Escape by Enhancing PD-1 and CTLA-4 Expression on T Lymphocytes in Hepatocellular Carcinoma
por: Bao, Shixiang, et al.
Publicado: (2021)

Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy
por: Kumar, Alok, et al.
Publicado: (2020)

Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes
por: Robert, Lidia, et al.
Publicado: (2014)

Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor models
por: Lewis, Katherine E., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4ar9rpuk73oa5nb658s0trt02u